Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial

PURPOSE: Subcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h) chemotherapy-induced nausea and vomiting (CINV). This randomized, double-blind phase 3 trial compared APF530 and palonosetron in preventing acute and delayed CINV after...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Support Care Cancer
Main Authors: Raftopoulos, Harry, Cooper, William, O’Boyle, Erin, Gabrail, Nashat, Boccia, Ralph, Gralla, Richard J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4311069/
https://ncbi.nlm.nih.gov/pubmed/25179689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-014-2400-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados